News Center

Home page

Peak Report

News reports

Announcement on Subsidiary Company Obtaining Drug Registration Certificate

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2020-023

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Subsidiaries Obtaining Drug Registration Certificate

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.

Important Content Note:

Obtaining the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical is qualified to produce and sell the drug, which will further enrich Jianfeng Pharmaceutical's product line and help enhance the competitiveness of the company's pharmaceutical business.
Risk Warning: Because pharmaceutical products have the characteristics of high technology, high risk, and high added value, not only the pre-research and development of drugs, the period from approval to production is long, the investment is large, and there are many links, and the drug has obtained the registration The production and sales after the certificate are also easily affected by factors such as national policies and market environment. Investors are requested to pay attention to investment risks.

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the Drug Registration Certificate of esomeprazole sodium for injection (Certificate No.: 2020S00572) approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of

1. Drugs
Drug Name: Esomeprazole Sodium for Injection
Dosage Form: Injection
Specification: 40mg (calculated by C ₁₇H ₁₉N ₃O ₃S)
Application Items: drug Registration (Domestic Production)
Registration Classification: Original Chemical Drug Category 6
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
acceptance number: CYHS1301863 Zhejiang
Certificate No.: 2020S00572
Drug Registration Standard No.: YBH03162020
Drug Validity Period: 12 Months
Drug Approval Number: the validity period of the drug approval document number of the national drug standard H20203449
is until August 25, 2025
approval conclusion: according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements for drug registration, is approved for registration, and a drug registration certificate is issued. The production process, quality standards, instructions and labels shall be in accordance with the attached.

2. Drug Development and Related Conditions
This product is used to treat:
1. as an alternative therapy for GERD when oral therapy is not applicable.
2. Use in low-risk patients with acute gastric or duodenal ulcer bleeding for whom oral therapy is not applicable (gastroscopic Forrest grading IIc-III).
Esomeprazole sodium for injection has been listed in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition)" and classified as Class B; it is not included in the "National Essential Drugs List (2018 Edition)". At present, 30 enterprises, including AstraZeneca Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Qilu Pharmaceutical Co., Ltd., and Shandong Luoxin Pharmaceutical Group Co., Ltd., have been approved for listing in China. According to the data of the intranet, the domestic sales in 2019 (including urban and county-level public hospitals, community and township health centers) are about 3.317 billion yuan.
Peak Pharmaceutical submitted an application for registration of the drug to the State Food and Drug Administration on November 28, 2013 and was accepted. Up to now, the research and development investment of esomeprazole sodium for injection project of Jianfeng Pharmaceutical Co., Ltd. is about 14.9128 million yuan. The impact of

3. on the company and its risks suggest that
Jianfeng Pharmaceutical already has a corresponding production line. The acquisition of the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug, which will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business. Due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the period from the preliminary research and development, approval to production is long, the investment is large and there are many links, but also the production and sales of drugs after obtaining the registration certificate are easily affected by national policies, market environment and other factors. Please pay attention to the investment risk.

This is to announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors
September 5, 2020

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页